Skip to main content

Call for papers - Cancer therapy: KRAS targeted therapies

Guest Editors

Biswarup Saha, MS, MTech, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA
Hitendra Singh Solanki, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA

Submission Status: Open   |   Submission Deadline: 21 November 2024

BMC Cancer is calling for submissions to our Collection on Cancer therapy: KRAS targeted therapies. We invite contributions on various aspects, including new and emerging research, analyses of clinical treatments, and studies across cancer types.

Meet the Guest Editors

Back to top

Biswarup Saha, MS, MTech, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA

As a scientist at the H. Lee Moffitt Cancer Center & Research Institute, Dr Saha’s fundamental research is based upon hippo signaling and its downstream mediator, focusing mainly on protooncogenic YAP1, and its associated molecular crosstalk under NFkB modulatory pathway in pan cancer. His research interests are: tumor biology, cancer stem cell, epigenetics, cell signaling, drug resistance, tumor microenvironment, extracellular matrix, and desmoplasia.

Hitendra Singh Solanki, PhD, H. Lee Moffitt Cancer Center & Research Institute, USA

Dr Solanki is a PhD scientist trained in cancer signaling, drug resistance in cancer and mass spectrometry-based phosphoproteomics. He uses multi-omics approaches to discern diverse mechanisms of adaptive and acquired resistance to KRAS (OFF)- and (ON)- state inhibitors in lung cancer.  His work primarily focused on conducting translational research and develop biomarkers to predict therapeutic responses in lung cancer.

About the Collection

One of the most frequently mutated oncogenes in human cancer, KRAS has long been considered “undruggable” with targeted therapy. As central drivers of cancer progressions, KRAS mutations function as oncogenic initiators, instigating the proliferation of malignant cells. The result is the rapid expansion of resistant malignant tissue. 

Targeting these mutations is imperative to advancing cancer therapy, and in light of recent developments in the field, BMC Cancer has launched this Collection on Cancer therapy: KRAS targeted therapies. 

We encourage submissions on a range of topics, including but not limited to:

  • Novel strategies, such as small molecule inhibitors, immunotherapies, and gene-based therapies, designed specifically for addressing KRAS-mutated cancers
  • Studies that assess the safety, effectiveness, and tolerability of KRAS targeted therapies across cancer types
  • Precise biomarkers and diagnostic tools
  • Potential synergistic effects arising from combining KRAS targeted agents with conventional cancer treatments
  • Mechanisms responsible for resistance to KRAS targeted therapies
  • Analyses of real-world clinical results

Image credit: LASZLO /

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select Cancer therapy: KRAS targeted therapies from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.